Joshua Todd, MD
Interventional Cardiology · Knoxville, TNNPI 1003017963
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,750 of the $45,100 with a category attached, or 70.4%. Abiomed accounts for 71.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $17,437 and has fallen 95.9% since, to $713 in 2025.
Across 211 payments — averaging $213.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$32K
- AstraZeneca$9K
- EKOS Corporation$1K
- Medtronic$1K
- Johnson & Johnson$1K
- Boston Scientific$284
- plus $336 from 7 others
Across 15 payments — averaging $11,620 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$92K
- AstraZeneca$82K
- Abiomed$59
What the payments were for
- Speaking & faculty fees$31,75070%
- Travel & lodging$5,74813%
- Food & beverage$7,55817%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 59 | $32,053 |
| AstraZeneca | 29 | $8,570 |
| EKOS Corporation | 10 | $1,475 |
| Medtronic(2 entities) | 63 | $1,256 |
| Johnson & Johnson | 27 | $1,126 |
| Boston Scientific | 9 | $284 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $169 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| CSL Behring | 1 | $29 |
| Amgen | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| GE HealthCare | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,100 in reported general payments places this provider in the 80th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 553 | $607,193 |
| XareltoRivaroxaban | 156 | $175,464 |
| FarxigaDapagliflozin Propanediol | 120 | $110,969 |
| EntrestoSacubitril/Valsartan | 48 | $57,135 |
| BrilintaTicagrelor | 44 | $29,616 |
| Repatha SyringeEvolocumab | 17 | $20,859 |
| Repatha SureclickEvolocumab | 16 | $19,410 |
| JardianceEmpagliflozin | 19 | $15,986 |
| Repatha PushtronexEvolocumab | 12 | $8,209 |
| Atorvastatin Calcium | 807 | $7,558 |
| SotalolSotalol Hcl | 271 | $5,117 |
| Flecainide Acetate | 88 | $4,799 |
| Dofetilide | 52 | $4,109 |
| Metoprolol Succinate | 398 | $3,630 |
| Losartan Potassium | 474 | $3,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $1,126 | $175,464156 claims |
| AstraZenecaFarxiga, Brilinta | $8,570 | $140,585164 claims |
| Boehringer IngelheimJardiance, Pradaxa | $19 | $17,99830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Knoxville
- Malcolm FosterKnoxville$413K
- Ayaz RahmanKnoxville$251K
- Sara NegrottoKnoxville$114K
- Stuart BreseeKnoxville$112K
- Rachel GoodwinKnoxville$74K
- Morgan RandallKnoxville$29K
- Briana CostelloKnoxville$28K
- Barry MichelsonKnoxville$17K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.